These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 37100113)

  • 1. G protein-coupled receptor-targeting antibody-drug conjugates: Current status and future directions.
    High P; Carmon KS
    Cancer Lett; 2023 Jun; 564():216191. PubMed ID: 37100113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment.
    Pramanik D
    Anticancer Agents Med Chem; 2023; 23(6):642-657. PubMed ID: 36321237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.
    Rossi C; Chrétien ML; Casasnovas RO
    Target Oncol; 2018 Jun; 13(3):287-308. PubMed ID: 29556925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update of antibody-drug conjugates for hematological malignancies.
    Sun W; Hu S; Wang X
    Curr Opin Oncol; 2024 Sep; 36(5):430-436. PubMed ID: 39007226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Drug Conjugates-A Tutorial Review.
    Baah S; Laws M; Rahman KM
    Molecules; 2021 May; 26(10):. PubMed ID: 34063364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions.
    Yu J; Li M; Liu X; Wu S; Li R; Jiang Y; Zheng J; Li Z; Xin K; Xu Z; Li S; Chen X
    Biomed Pharmacother; 2024 May; 174():116522. PubMed ID: 38565055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads.
    Xi M; Zhu J; Zhang F; Shen H; Chen J; Xiao Z; Huangfu Y; Wu C; Sun H; Xia G
    Eur J Med Chem; 2024 Oct; 276():116709. PubMed ID: 39068862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-drug conjugates in solid tumors; new strategy for cancer therapy.
    Takakura T; Shimizu T; Yamamoto N
    Jpn J Clin Oncol; 2024 Aug; 54(8):837-846. PubMed ID: 38704241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The next generation of antibody drug conjugates.
    Mack F; Ritchie M; Sapra P
    Semin Oncol; 2014 Oct; 41(5):637-52. PubMed ID: 25440608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-Drug Conjugates: The New Frontier of Chemotherapy.
    Ponziani S; Di Vittorio G; Pitari G; Cimini AM; Ardini M; Gentile R; Iacobelli S; Sala G; Capone E; Flavell DJ; Ippoliti R; Giansanti F
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stepping forward in antibody-drug conjugate development.
    Jin Y; Schladetsch MA; Huang X; Balunas MJ; Wiemer AJ
    Pharmacol Ther; 2022 Jan; 229():107917. PubMed ID: 34171334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving landscape of antibody-drug conjugates in gynecologic cancers.
    Tolcher A; Hamilton E; Coleman RL
    Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies.
    Amani N; Dorkoosh FA; Mobedi H
    Curr Drug Deliv; 2020; 17(1):23-51. PubMed ID: 31755387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies.
    Ma H; Sawas A
    Curr Hematol Malig Rep; 2018 Dec; 13(6):555-569. PubMed ID: 30362019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Drug Conjugates for Cancer Therapy.
    Hafeez U; Parakh S; Gan HK; Scott AM
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
    Hong Y; Nam SM; Moon A
    Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-drug conjugates in hematologic malignancies.
    Leslie LA; Younes A
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
    Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
    Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug conjugate-based anticancer therapy - Current status and perspectives.
    Yang Y; Wang S; Ma P; Jiang Y; Cheng K; Yu Y; Jiang N; Miao H; Tang Q; Liu F; Zha Y; Li N
    Cancer Lett; 2023 Jan; 552():215969. PubMed ID: 36279982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.